Michelle Tharp-grozinger, AMFT - in Newport Beach, CA

Healthcare Provider's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

News Archive

15% strokes occur during sleep making treatment difficult: Study

According to a new study nearly 15 percent of people who have a stroke are not eligible for clot-busting treatment because the stroke happened while they slept. These clot breaking drugs can prevent permanent disability after a stroke - but the treatment must be given within a four-and-a-half-hour window after the stroke symptoms begin say experts. Since people who have a stroke while asleep can't know when it occurred, they can't get the treatment if they slept for more than four and a half hours, explained study author Dr. Jason Mackey at the University of Cincinnati. "They can't get the drug," he said. "That's a big issue."

African Sahel faces food insecurity despite record increase in cereal production; New partnership to address food supply in Middle East, North Africa

"According to the U.N. Food and Agriculture Organization's (FAO) quarterly forecast of agricultural production and food," the world is expected to see a record increase in cereal production in 2012, "[b]ut despite the positive global trends, countries in Africa's Sahel region continue to face serious challenges to food security due to locally high food prices and civil strife, FAO said in a news release," the U.N. News Centre reports.

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

Emory launches COVIDVu study to understand the extent of epidemic across the U.S.

Researchers from Emory University's Rollins School of Public Health were awarded a $6.6 million grant from the National Institutes of Health to launch COVIDVu, a national study that will use home tests to develop estimates of the current number of COVID-19 infections and persons with antibody response nationally and across seven heavily impacted states.

Research opens possibility of developing single-dose gene therapy for inherited arrhythmias

Researchers at Boston Children's Hospital report creating the first human tissue model of an inherited heart arrhythmia, replicating two patients' abnormal heart rhythms in a dish, and then suppressing the arrhythmia with gene therapy in a mouse model.

Read more News

› Verified 5 days ago